Lucinactant for Inhalation

COMBINATION_PRODUCT3 trials

Sponsors

Windtree Therapeutics

Conditions

Respiratory Distress SyndromeRespiratory Distress Syndrome, Newborn

Phase 2

Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates

CompletedNCT02074059

Windtree TherapeuticsRespiratory Distress Syndrome

Start: 2014-02-28End: 2015-11-30Updated: 2017-04-21

Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA

TerminatedNCT02528318

Windtree TherapeuticsRespiratory Distress Syndrome

Start: 2015-08-31End: 2017-08-11Updated: 2019-07-23

A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age

TerminatedNCT04264156

Windtree TherapeuticsRespiratory Distress Syndrome, Newborn

Start: 2020-04-18End: 2021-03-28Updated: 2023-05-24